Opinion|Videos|July 2, 2024
Implications of Real-World Data in the 1L Treatment of High-Risk CLL
Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Please outline your general treatment strategy for patients with high-risk CLL. How do recently presented real-world data influence your treatment approach?
Advertisement
Related to this article
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.
In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Five Under 5: Top Oncology Videos for the Week of 9/13
3
Olaparib Maintenance Yields Promising Long-Term OS Outcomes in Asian Patients With Platinum-Sensitive, Relapsed Ovarian Cancer
4
The OncFive: Top Oncology Articles for the Week of 9/14/2026
5